OpenNashEarnings

Biotechnology · Nasdaq: ALNY

Alnylam earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 11 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Alnylam enlarged its TRITON-CM nucresiran trial to about 2,250 patients, keeping a 2030 ATTR-CM launch, while AMVUTTRA's cardiomyopathy launch kept driving TTR growth.

AMVUTTRA's ATTR-CM launch remained the main driver of demand. U.S. prescriptions grew about 70% year over year, and more than 2,000 new prescribers have been added since March 2025. Abroad, ATTR-CM launches in Japan, Germany and Italy added to growth. New HELIOS-B analyses showed consistent benefit with or without baseline tafamidis. Brezosiran, for Huntington's disease, showed a 60-64% mean reduction of mutant huntingtin in spinal fluid.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$1.5B+16.7% y/yQ3 2026
Q4 2024: $593.2M (worked out from the annual figure)Q4 ’24$593.2MQ1 2025: $594.2MQ1 ’25$594.2MQ2 2025: $773.7MQ2 ’25$773.7MQ3 2025: $1.2BQ3 ’25$1.2BQ4 2025: $1.1B (worked out from the annual figure)Q4 ’25$1.1BQ2 2026: $1.3BQ2 ’26$1.3BQ3 2026: $1.5BQ3 ’26$1.5B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$593.2M *
Q1 2025$594.2M
Q2 2025$773.7M
Q3 2025$1.2B
Q4 2025$1.1B *
Q2 2026$1.3B
Q3 2026$1.5B
Diluted EPS (GAAP)$15.72+634.6% y/yQ3 2026
Q1 2025: -$0.14Q1 ’25-$0.14Q2 2025: -$0.55Q2 ’25-$0.55Q3 2025: $2.14Q3 ’25$2.14Q2 2026: $1.21Q2 ’26$1.21Q3 2026: $15.72Q3 ’26$15.72
Data
Q1 2025-$0.14
Q2 2025-$0.55
Q3 2025$2.14
Q2 2026$1.21
Q3 2026$15.72

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin23.7%−5.8 pts y/yQ3 2026
Q4 2024: -17.7%Q4 ’24-17.7%Q1 2025: 3.0%Q1 ’253.0%Q2 2025: -2.1%Q2 ’25-2.1%Q3 2025: 29.5%Q3 ’2529.5%Q4 2025: 12.0%Q4 ’2512.0%Q2 2026: 17.9%Q2 ’2617.9%Q3 2026: 23.7%Q3 ’2623.7%
Data
Q4 2024-17.7%
Q1 20253.0%
Q2 2025-2.1%
Q3 202529.5%
Q4 202512.0%
Q2 202617.9%
Q3 202623.7%
Free cash flow$271.2M−4.8% y/yQ3 2026
Q4 2024: -$103.8MQ4 ’24-$103.8MQ1 2025: -$127.3MQ1 ’25-$127.3MQ2 2025: $113.5MQ2 ’25$113.5MQ3 2025: $284.7MQ3 ’25$284.7MQ4 2025: $194.4MQ4 ’25$194.4MQ3 2026: $271.2MQ3 ’26$271.2M
Data
Q4 2024-$103.8M
Q1 2025-$127.3M
Q2 2025$113.5M
Q3 2025$284.7M
Q4 2025$194.4M
Q3 2026$271.2M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$593.2Md$594.2M$773.7M$1.2B$1.1Bd—$1.3B$1.5B
Operating income-$105.2Md$18.1M-$16.2M$368.0M$131.7Md—$231.4M$345.8M
Operating margin-17.7%3.0%-2.1%29.5%12.0%—17.9%23.7%
Net income-$83.8Md-$18.3M-$72.2M$292.7M$111.5Md$206.0M$164.5M$2.2B
Diluted EPS—-$0.14-$0.55$2.14——$1.21$15.72
Operating cash flow-$94.7Md-$118.3M$127.8Md$296.9Md$217.7Md——$341.0Md
Capital expenditure$9.1Md$9.0M$14.3Md$12.1Md$23.3Md——$69.8Md
Free cash flow-$103.8M-$127.3M$113.5M$284.7M$194.4M——$271.2M
R&D expense$300.2Md$265.1M$323.6M$358.8M$372.2Md—$413.1M$408.5M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings